Saturday 17 October 2026
Export LKFT’s income statement to Excel — free account
Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
29.90
0.03
−0.10%
Follow LKFT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 11.59 | 0.00 | 0.00 | 0.00 | 0.00 | 80.17 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 4 | 5 | 2 | 3 | 1 | 5 | 3 | 1 | 7 |
P/S ratio |
4.92 | 3.28 | 4.69 | 5.47 | 6.30 | 10.63 | 11.88 | 12.74 | 50.39 | 47.10 |
Altman Z-Score |
8.43 | 1.55 | 1.81 | 1.47 | 1.60 | 2.01 | 3.37 | 11.54 | 9.60 | 5.86 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.36 | 0.00 | 37.59 | 20.29 |
Altman Z″-Score (non-manufacturers) |
26.33 | 6.81 | 6.74 | 5.63 | 6.07 | 5.95 | 7.02 | 9.83 | 8.10 | 7.52 |
Beneish M-Score |
0.34 | (1.32) | (1.39) | (2.43) | (2.47) | (0.19) | (3.53) | (1.63) | (1.60) | (2.31) |
P/Operating CF |
(8.77) | (6.32) | (7.38) | (14.26) | (18.51) | (201.04) | (110.41) | (82.58) | (43.14) | 10.41 |
P/B ratio |
0.75 | 0.58 | 0.95 | 1.09 | 1.15 | 2.11 | 3.70 | 3.33 | 3.59 | 3.59 |
Price to Tangible BV |
0.75 | 0.63 | 1.03 | 1.20 | 1.18 | 2.17 | 3.73 | 3.34 | 3.59 | 3.60 |
EV/Sales |
(3.21) | (3.44) | (2.44) | (2.60) | (3.37) | 0.95 | 5.45 | 8.68 | 33.88 | 29.35 |
EV/EBITDA |
3.70 | 7.32 | 5.86 | 5.73 | 11.32 | 0.00 | 12.95 | 0.00 | 0.00 | 62.85 |
EV/Operating CF |
2.01 | 2.21 | 1.75 | 2.62 | 3.24 | (1.17) | 1.52 | (19.35) | 23.69 | 11.98 |
EV/FCF |
1.74 | 1.84 | 1.69 | 2.45 | 2.91 | (0.97) | 1.54 | (17.65) | 25.27 | 12.64 |
Quick Ratio |
19.95 | 9.69 | 8.76 | 7.96 | 8.53 | 8.40 | 10.24 | 6.01 | 6.94 | 9.63 |
Current Ratio |
20.15 | 9.97 | 9.02 | 8.11 | 8.58 | 8.45 | 10.26 | 6.04 | 6.98 | 9.70 |
Net Debt/EBITDA |
(8.53) | 22.11 | 82.46 | 20.20 | 35.77 | 32.11 | (15.05) | 32.49 | 13.46 | 134.07 |
Debt/Assets |
0.15% | 0.00% | 0.11% | 0.31% | 0.37% | 0.43% | 0.33% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.30 | 0.06 | 0.05 | 0.10 | 0.09 | 0.09 | 0.24 | 0.24 | 0.13 | 0.20 |
Operating CF/Net income |
(0.80) | (4.32) | (1.92) | 2.30 | 4.88 | 1.40 | 21.41 | 4.87 | 1.27 | 4.43 |
Capex/Depreciation |
(0.24) | (1.80) | (0.39) | (0.55) | (1.67) | (4.89) | (3.67) | (2.70) | (1.73) | (1.14) |
Interest Coverage |
103.05 | (112.78) | (33.78) | (15.13) | (5.36) | (1.17) | 6.16 | (16.37) | (2.94) | (6.79) |
| 10.68% | 2.60% | 8.06% | (7.94%) | (3.95%) | (11.13%) | 7.21% | (2.68%) | (13.19%) | 9.60% | |
| 8.72% | 1.74% | 4.72% | (4.13%) | (1.93%) | (5.24%) | 3.95% | (2.19%) | (9.86%) | 7.07% | |
ROIC |
75.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
10.67% | 2.37% | 5.95% | (5.63%) | (2.33%) | (6.31%) | 2.80% | (2.58%) | (11.10%) | 5.88% |
Average Days of Receivables |
17.04 | 115.67 | 100.32 | 48.08 | 96.48 | 118.75 | 30.95 | 34.23 | 93.05 | 47.87 |
Research and Development Expense of Revenue |
41.31% | 121.70% | 100.65% | 101.94% | 101.42% | 98.76% | 47.70% | 101.58% | 140.14% | 92.06% |
Selling, General and Administrative Expense of Revenue |
13.79% | 48.77% | 55.88% | 57.89% | 43.49% | 34.93% | 10.97% | 12.51% | 17.46% | 15.52% |
Intangible Assets out of Total Assets |
0.00 | 0.06 | 0.05 | 0.05 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2.16% | 7.21% | 23.66% | 17.52% | 14.59% | 15.08% | 4.27% | 8.42% | 10.61% | 7.28% |
Graham Net Nets |
1.14 | 1.37 | 0.85 | 0.73 | 0.76 | 0.41 | 0.25 | 0.27 | 0.26 | 0.25 |
Graham Number |
0.00 | 0.00 | 50.47 | 0.00 | 0.00 | 0.00 | 56.97 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.40%) | 8.63% | (5.68%) | (7.73%) | (3.38%) | (5.42%) | 1.25% | (0.78%) | (2.04%) | (3.49%) |
Free Cash Flow Yield |
(37.55%) | (56.90%) | (30.74%) | (19.41%) | (18.40%) | (9.20%) | 29.73% | (3.86%) | 2.66% | 4.93% |
Revenue per Share |
19.10 | 4.53 | 3.94 | 8.10 | 8.76 | 9.31 | 17.42 | 7.20 | 3.56 | 3.67 |
Operating CF per Share |
(4.42) | (5.26) | (6.67) | (8.03) | (9.10) | (7.50) | 62.37 | (3.23) | (3.36) | 5.80 |
Capex per Share |
(0.23) | (1.35) | (0.28) | (0.58) | (1.05) | (1.60) | (0.89) | (0.31) | (0.17) | (0.12) |
Free Cash Flow per Share |
(4.65) | (6.60) | (6.95) | (8.61) | (10.15) | (9.10) | 61.49 | (3.54) | (3.53) | 5.68 |
Cash per Share |
51.47 | 51.87 | 60.53 | 65.66 | 84.95 | 90.60 | 112.38 | 29.25 | 26.30 | 23.73 |
Shareholders Equity per Share |
55.56 | 47.57 | 45.92 | 40.51 | 47.75 | 46.87 | 55.90 | 27.52 | 23.12 | 18.37 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
55.56 | 47.57 | 45.92 | 40.51 | 47.75 | 46.87 | 55.90 | 27.52 | 23.12 | 18.37 |
Free Cash Flow |
(306.44) | (435.15) | (457.61) | (565.52) | (664.55) | (592.40) | 3,542.48 | (184.45) | (174.59) | 259.64 |
Working Capital |
3,311.15 | 3,251.03 | 3,715.93 | 3,913.40 | 5,081.86 | 5,407.73 | 5,929.43 | 1,309.67 | 1,159.63 | 999.75 |
Capital Expenditures |
(15.16) | (88.85) | (18.23) | (38.15) | (68.48) | (104.25) | (51.17) | (16.20) | (8.40) | (5.28) |
Net Current Asset Value |
3,291.02 | 2,273.14 | 2,489.03 | 2,137.25 | 2,735.39 | 2,652.39 | 2,993.73 | 1,303.36 | 1,043.67 | 755.36 |
EV/EBIT |
4.41 | 10.04 | 6.03 | 4.91 | 9.85 | 0.00 | 13.18 | 0.00 | 0.00 | 69.80 |
Capex to Sales |
0.01 | 0.30 | 0.07 | 0.07 | 0.12 | 0.17 | 0.05 | 0.04 | 0.05 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.73 | 0.00 | 0.00 | 112.01 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.69 | 0.37 | 0.35 | 0.43 | 0.25 | 0.18 | 0.19 | 0.22 | 0.26 | 0.28 |
Cash ROIC |
(4.34%) | (6.64%) | (6.52%) | (8.09%) | (7.63%) | (6.60%) | 36.45% | (6.23%) | (7.14%) | 13.50% |
Accounts Receivable Turnover |
16.42 | 3.60 | 3.67 | 4.80 | 3.29 | 4.29 | 16.68 | 9.37 | 5.27 | 9.18 |
Accounts Payable Turnover |
0.30 | 0.30 | 0.00 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.83 | 0.56 | 0.00 | 0.32 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
1,284.51 | 1,035.20 | 0.00 | 4,492.63 | 30,789.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
276.09 | 535.96 | 0.00 | 1,599.28 | 4,608.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
76.63 | 82.92 | 70.71 | 110.88 | 174.35 | 141.07 | 60.14 | 40.07 | 33.46 | 18.27 |
Average Payables |
112.70 | 126.66 | 151.49 | 159.61 | 179.75 | 178.78 | 121.03 | 67.33 | 43.93 | 33.67 |
Average Inventory |
40.42 | 67.73 | 67.91 | 40.05 | 12.17 | 0.00 | 0.00 | 0.16 | 0.32 | 0.35 |
Average Assets |
4,164.70 | 4,595.64 | 4,852.06 | 5,566.07 | 6,337.70 | 6,664.10 | 4,248.44 | 1,576.96 | 1,326.35 | 845.09 |
Average Common Equity |
3,397.92 | 3,080.21 | 2,843.53 | 2,894.39 | 3,088.85 | 3,135.54 | 2,327.38 | 1,288.94 | 991.71 | 622.44 |
Columns are period end dates